findmyKOL

Valerie Espinosa, MD

Basic profile

Texas Diabetes & Endocrinology

ORCIDNone on fileNPI↗
✓ Full record
RegionAustin, TX · South CentralSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLEmergingfindmyKOL type: RegionalLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Valerie Espinosa is an Endocrinology/Metabolic physician affiliated with Texas Diabetes & Endocrinology. OpenAlex indexes 10 publications with 1,409 citations (h-index 6).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
10publications

Distinct works indexed by OpenAlex.

1,409citations

Total citations across indexed works.

6h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
19companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

6500 North Mo Pac Expressway
Building 3, Suite 200
Austin, TX 78731

Telephone

512-458-8400

Registry record last updated 6 Jan 2011.

View the NPPES registry record

Industry payments

19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Hormonal (systemic)

    44.8%
    l-Thyroxine39%
    Levothyroxine Sodium64%Synthroid31%Tirosint3%Unithroid1%Levoxyl1%
    Part D<11 patients
    l-Triiodothyronine2.1%
    Liothyronine Sodium100%
    Part D≥25 patients

    + 4 more classes in this area

  • Metabolism & gastrointestinal

    28.6%
    GLP-1 receptor agonist8.9%
    Ozempic60%Mounjaro24%Trulicity16%
    Part D≥40 patients
    Biguanide (metformin)5.7%
    Metformin Hcl Er76%Metformin Hcl24%
    Part D≥58 patients

    + 9 more classes in this area

  • Cardiovascular

    19.2%
    Statin10%
    Rosuvastatin Calcium40%Atorvastatin Calcium37%Simvastatin13%Livalo6%Pravastatin Sodium5%
    Part D<11 patients
    Thiazide diuretic2.2%
    Hydrochlorothiazide100%
    Part D≥28 patients

    + 8 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”